The primary objectives of this study are to investigate

• the safety and tolerability of increasing single oral doses of BAY 1830839 versus placebo under fasted conditions
• the pharmacokinetics after single ascending oral doses of BAY 1830839 under fasted conditions

Inclusion Criteria:

• Body mass index (BMI) : ≥18.5 and ≤30 kg/m*2

Exclusion Criteria:

• Relevant diseases within the last 4 weeks prior to the first study drug administration
• Febrile illness within 4 weeks before the first study drug administration
• Known hypersensitivity to the study drugs or components of the preparations
• Clinically relevant findings in the physical examination